Vicriviroc
Articles on Vicriviroc Merck Decides to Stop Development of Vicriviroc for Treatment of HIV 7/16/2010 Vicriviroc Fails to Beat Stiff Competition, Merck Will Not File for Treatment-experienced Approval 2/19/2010 Experimental CCR5 Antagonist Vicriviroc Appears Safe and Well Tolerated in HIV/HCV Coinfected Patients 1/12/2010 CCR5 Antagonist Vicriviroc Demonstrates Greater Efficacy in Patients Identified Using More Sensitive CCR5 Tropism Test 1/12/2010 CCR5 Antagonist Vicriviroc Demonstrates Long-Term Safety and Efficacy at 96 Weeks 9/14/2009 Assessment of Pharmacokinetic and Safety Interactions Between Vicriviroc and CYP3A4 Substrates, Inhibitors, and Inducers 9/14/2009 Clonal Analysis of the gp120 V3 Loop from Clinical Isolates Displaying Phenotypic Resistance to Vicriviroc 9/14/2009 Vicriviroc Long-term Safety and Efficacy: 96-Week Results from the VICTOR-E1 Study 9/14/2009 Comparison of Trofile® and ViroTectTropism Assays in Treatment-Experienced Subjects 2/10/09. Rapamycin Enhances Anti-HIV Activity of Experimental CCR5 Antagonist Vicriviroc 1/16/09 Long-term Safety of Vicriviroc 11/05/2008 Low Doses of CCR5 Antagonist Vicriviroc Do Not Suppress HIV as well as Efavirenz (Sustiva) in Treatment-naive Patients; New Study Underway 10/14/08 Schering-Plough Initiates Phase II Study with Vicriviroc in Treatment-naïve HIV-infected Patients 4/16/08 CCR5 Antagonist Vicriviroc Shows Continued Benefits and Good Tolerability at 48 Weeks: VICTOR-E1 Trial 2/05/08 Vicriviroc, a Next Generation CCR5 Antagonist, Exhibits Potent, Sustained Suppression of Viral Replication in Treatment-Experienced Adults: VICTOR-E1 48-week Results. 2/10/08 Vicriviroc, a Next Generation CCR5 Antagonist, Exhibits Potent, Sustained Suppression of Viral Replication in Treatment-Experienced Adults: VICTOR-E1 48-week Results 2/05/08 Effect of Virus Concentration on in vitro Measurement of Phenotypic Resistance to the CCR5 Antagonist Vicriviroc. 2/05/08
